Cediranib

Cediranib
Clinical data
Routes of; administration	Oral
ATC code	L01EK02 (WHO) ;
Pharmacokinetic data
Elimination half-life	12 to 35 hours
Identifiers
	IUPAC name 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline;
CAS Number	288383-20-0 ;
PubChem CID	9933475;
IUPHAR/BPS	5664;
ChemSpider	8109103 ;
UNII	NQU9IPY4K9;
KEGG	D08881;
ChEMBL	ChEMBL491473 ;
CompTox Dashboard (EPA)	DTXSID10183035 ;
ECHA InfoCard	100.196.628
Chemical and physical data
Formula	C25H27FN4O3
Molar mass	450.514 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COc4cc3c(Oc2ccc1[nH]c(C)cc1c2F)ncnc3cc4OCCCN5CCCC5;
	InChI InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3 ; Key:XXJWYDDUDKYVKI-UHFFFAOYSA-N ;
	(what is this?) (verify)

Cediranib (AZD-2171; tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.

The drug is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.